Comparative Pharmacology
Head-to-head clinical analysis: CEFUROXIME SODIUM versus KEFLIN IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFUROXIME SODIUM versus KEFLIN IN PLASTIC CONTAINER.
CEFUROXIME SODIUM vs KEFLIN IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime sodium is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Cephalothin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activity, leading to cell lysis and death.
750 mg to 1.5 g IV or IM every 8 hours; maximum 6 g per day.
1 to 2 g IV or IM every 4 to 6 hours. Maximum 12 g/day.
None Documented
None Documented
Terminal elimination half-life: 1.2 hours (range 1-2 hours) in patients with normal renal function; prolonged to 15-22 hours in end-stage renal disease (CrCl <10 mL/min); dosing adjustment required for CrCl <30 mL/min
0.5-1 hour in normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <10 mL/min)
Renal (95% unchanged via glomerular filtration and tubular secretion); biliary/fecal (minimal, <5%)
Renal: 60-80% unchanged; biliary/fecal: minimal (<1%)
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic